Fig. 5

Evaluation of pain condition with the treatment of PCL, PCL/2% celecoxib nano fibers, and PCL/6% celecoxib nano fibers. a Hot plate test and b Von Frey test of rabbits treated with PCL, PCL/2% celecoxib nano fibers, and PCL/6% celecoxib nano fibers for 0 weeks, 4 weeks, 8 weeks, and 12 weeks. c–d IHC analysis of CGRP, NUEN, and DAPI of DRG of rabbit treated with PCL, PCL/2% celecoxib nano fibers, and PCL/6% celecoxib nano fibers for 6 weeks and 12 weeks. *P < 0.05 compared with the puncture group, ^#P < 0.05 compared with the puncture + PCL celecoxib group, and ^†P < 0.05 compared with the puncture + PCL/2% celecoxib group